Randomized comparison of abciximab i.v. versus i.c. in primary PCI patients with STEMI and effects on infarct size and microvascular obstruction

Trial Profile

Randomized comparison of abciximab i.v. versus i.c. in primary PCI patients with STEMI and effects on infarct size and microvascular obstruction

Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Abciximab (Primary) ; Abciximab (Primary)
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms LIPSIABciximab-STEMI
  • Most Recent Events

    • 17 Nov 2011 Results reporting the endpoint of aborted myocardial infarction published in the International Journal of Cardiology.
    • 01 May 2011 Results published in Clinical Research in Cardiology.
    • 28 Aug 2010 Results from mid-term follow-up at 6 months presented in an abstract at the Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top